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Introduction Atrial fibrillation (AF) is the commonest abnormal
heart rhythm with significant related morbidity and mortality.
There is increasing evidence that abnormalities of the cardiac
autonomic nervous system (ANS) are involved in the patho-
genesis of AF. Exploring the ANS is possible through heart
rate variability (HRV) evaluation. We aimed to investigate
whether HRV is more abnormal in patients with permanent
AF compared to paroxysmal AF.
Methods In a cross-sectional comparison, we studied two
patient groups: permanent AF (n = 30) and paroxysmal AF
(n = 31). Time-domain, frequency-domain and non-linear
measures of HRV were determined using eMotion Faros ECG
sensor. Participant’s breathing was controlled with a metro-
nome. Data was analysed using SPSS software.
Results Time-domain and non-linear indices of HRV were sig-
nificant higher in permanent AF group compared to paroxys-
mal AF (table 1). Permanent AF was the only independent
predictor of HRV on multivariable analysis in this cohort of
patients (p=0.006).
Conclusions HRV indices were significantly higher in perma-
nent AF compared to paroxysmal AF which may suggest pro-
nounced cardiac autonomic influence in the pathophysiology
of permanent AF.
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Background Atrial High-Rate Episodes (AHRE), as detected by
implantable cardiac devices, increase stroke risk. Remote moni-
toring (RM) provides physicians with timely notification of
such episodes through automatic downloads from home. The
AHRE burden required to increase thromboembolic risk is
unclear albeit the European Society of Cardiology (ESC) AF
guidelines recommend initiating oral anticoagulation (OAC) in
patients with at least a single episode of long duration (≥ 1
hour) and an overall ‘high’ daily burden of AHRE (total dura-
tion of all episodes), having considered the CHA2DS-VAS2C
score. Moreover, device manufacturers are inconsistent with
their nominal AHRE notification settings.
Aim In light of the ESC AF guidelines (2020), this study
reviewed the current practise of RM for AHRE detection to
determine OAC in patients with AHRE and CHA2DS-Vas2c ≥
2 (Male) or 3 (Female).
Methods We retrospectively collected data from 50 patients
with RM devices at a district hospital in the UK. Patients
were selected to allow comparison between the 4 different
manufacturers (Abbott, Biotronik, Boston Scientific, and Med-
tronic) used at the centre (figure 1). The latest AHRE notifi-
cation alert settings and clinical data were obtained from
electronic patient records. Table 1 shows the nominal
settings.
Results Of the 50 patients, 50% had dual chamber pacemaker
(figure 2), mean age 74 (SD ± 9) years, 38 patients (76%)
had no documented history of atrial fibrillation at device
implantation: 37 of them had an elevated CHA2DS-Vas2c
score or previous TIA/stroke. Of these 37 patients, 33
patients had nominal RM settings with 8 of these patients
later anticoagulated for AF; 4 patients had AHRE burden
settings reduced to 1 hour, with one of these patients later
anticoagulated for AF. DiscussionAbbott can alert for single,
prolonged AHRE episodes in accordance with ESC guidance.
However, episode detection is nominally set at 3 hours.
AHRE burden can be determined by all manufacturers and
may be used solely (without supporting guidance) in the
absence of single episode alerts, pending robust trial data to
conclusively alter the current OAC recomendation. Also, it is
apparent that RM nominal settings are not actively altered
by device implanting physicians but this may change as a
result of the recently revised ESC AF guidance.In our cohort,
37 patients without a history of AF at device implantation
were at significant risk of thromboembolism in the event of








Mean ± SD / Median [IQR] Mean ± SD / Median [IQR]
Age, years 70 ± 8 72 ± 11 0.64
CHA2DS2-VASc
score
3 [2 – 4] 3 [2 – 4] 0.56
BMI (kg/m2) 31.1 ± 5.1 31.0 ± 6.3 0.95
Systolic BP
(mmHg)
140 [128 – 148] 144 [134 – 153] 0.24
Diastolic BP
(mmHg)
81 ± 13 76 ± 15 0.16
Ejection fraction
(%)
55 [55 – 62] 62 [55 – 68] 0.22
HRV
measurements
Mean [95% CI] / Median
[95% CI]





75 [68 – 82]a 66 [60 – 71]a 0.03
SDNN (ms) 90 [82 – 113]b 39 [28 – 59]b <0.001
rMSSD (ms) 103 [97 – 118]b 33 [23 – 54]b 0.002
pNN50 (%) 64 [61 – 70]b 11 [4 – 28]b <0.001
SD1 (ms) 72 [69 – 80]b 23 [17 – 38]b <0.001
SD2 (ms) 104 [96 – 137]b 51 [35 – 65]b <0.001
Normally distributed data are expressed as mean [95% confidence intervals (CI)]. Identified
by superscript a.Non-normally distributed data are displayed as median [95% CI]. Identified
bysuperscript b. Normality test was performed using Shapiro-Wilk test. Statistical differen-
ces were tested using independent t-test (for parametricdata) or Mann-Whitney U test (for
non-parametric data). Significance p > 0.05.
AF = atrial fibrillation; SDNN = standard deviation of all NN intervals; rMSSD = square
root of the mean of the sum of thesquares of differences between adjacent NN intervals;
pNN50 = NN50 countdivided by the total number of all NN intervals
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